AGENUS INC Deferred Tax Assets, Gross
AGENUS INC (AGEN) had Deferred Tax Assets, Gross of $406.65 million as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsGross · last filed 2026-03-16
- 2025-12-31: Deferred Tax Assets, Gross $406.65M.
- 2024-12-31: Deferred Tax Assets, Gross $416.75M.
- 2023-12-31: Deferred Tax Assets, Gross $392.33M.
- 2022-12-31: Deferred Tax Assets, Gross $364.81M.
| Period end | Deferred Tax Assets, Gross |
|---|---|
| 2025-12-31 | $406.65M 10-K · filed 2026-03-16 |
| 2024-12-31 | $416.75M 10-K · filed 2026-03-16 |
| 2023-12-31 | $392.33M 10-K · filed 2025-03-17 |
| 2022-12-31 | $364.81M 10-K · filed 2024-03-14 |
| 2021-12-31 | $305.73M 10-K · filed 2023-03-16 |
| 2020-12-31 | $311.79M 10-K · filed 2022-03-01 |
| 2019-12-31 | $264.39M 10-K · filed 2021-03-16 |
| 2018-12-31 | $255.07M 10-K · filed 2020-03-16 |
| 2017-12-31 | $235.81M 10-K · filed 2019-03-18 |
| 2016-12-31 | $301.05M 10-K · filed 2018-03-16 |
| 2015-12-31 | $266.49M 10-K · filed 2017-03-16 |
| 2014-12-31 | $235.20M 10-K · filed 2016-03-15 |
| 2013-12-31 | $212.88M 10-K · filed 2015-03-16 |
| 2012-12-31 | $204.32M 10-K · filed 2014-03-07 |
| 2011-12-31 | $202.02M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |